60 Degrees Pharmaceuticals, INC 8-K filings

60 Degrees Pharmaceuticals has announced ethics approval for an expanded access study of tafenoquine for babesiosis, aiming to confirm promising results from a previous case series.

60 Degrees Pharmaceuticals has enrolled the first patient in a clinical trial to evaluate tafenoquine as a treatment for babesiosis, a tick-borne disease.

60 Degrees Pharmaceuticals has been granted FDA orphan drug designation for tafenoquine in the treatment of acute babesiosis, qualifying the company for incentives like market exclusivity and tax credits.

60 Degrees Pharmaceuticals announced that the FDA provided comments on their tafenoquine babesiosis clinical trial protocol, with no material changes required, allowing the trial to proceed as planned.

60 Degrees Pharmaceuticals has announced that the FDA will provide feedback on their babesiosis trial protocol in April 2024, a delay from the previously anticipated March timeline.

60 Degrees Pharmaceuticals has received a notice from Nasdaq stating that its common stock has not maintained the minimum required bid price, potentially leading to delisting.

60 Degrees Pharmaceuticals will sponsor pre-clinical studies at Monash University to investigate the efficacy of tafenoquine against Candida spp, including the drug-resistant Candida auris.

60 Degrees Pharmaceuticals successfully closed a $2.4 million public offering to support working capital, general corporate purposes, and the relaunch of its malaria prevention project.

60 Degrees Pharmaceuticals plans to initiate a pivotal clinical study for tafenoquine to treat hospitalized babesiosis patients after a positive Type C meeting with the FDA.

60 Degrees Pharmaceuticals has regained compliance with Nasdaq's minimum bid price rule after its stock price closed at or above $1.00 for ten consecutive days.